Regeneron Pharmaceutical Inc.’s REGN-COV2 has been authorized by the U.S. drug regulators to treat early, mild to moderate COVID-19 symptoms in adults and some children of at least 12 years, according to Regneron’s press release. Regeneron expects to have treatment doses for about 80,000 patients by the end of this month, 200 patients by the end of the first week of January, and 300,000 patients by the end of January.
- Regeneron’s therapy appears to be most beneficial in patients who hadn’t yet produced coronavirus antibodies on their own
- Regeneron’s treatment was given to President Donald Trump last month when he was diagnosed with COVID-19.
- In October’s trial findings, Regeneron’s cocktail was found to treat patients outside the hospital, reducing virus loads and the need for further medical care.
- Regeneron has secured a $450 million supply deal from Operation Warp Speed to accelerate vaccines and treatments for COVID-19.
Regeneron’s stock is currently gaining. REGN: NASDAQ is up 5.09% on premarket.
